Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies

Bartlett, Marissa L.; Webb, Myles; Durrant, Simon; Morton, James A.; Allison, Roger; Macfarlane, David J.
November 2002
European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 11, p1470
Academic Journal
Standard treatment regimens for haematological malignancies include myeloablative chemoradiotherapy and subsequent rescue by stem cell transplantation. However, these treatment regimens have significant associated mortality and morbidity, and disease recurrence remains a problem. One alternative approach is the targeted delivery of radiotherapy to the marrow using a bone-seeking agent labelled with an appropriate radioisotope, with the aim of delivering a potentially ablative radiation dose to marrow while minimising non-haematological toxicity. Pharmacokinetics and radiation dosimetry for a commercial preparation of samarium-153 ethylene diamine tetramethylene phosphonate (EDTMP; Quadramet) were evaluated in 43 tracer (average dose 740 MBq) studies of 42 patients with haematological malignancies. Measurements of 24-h retention were also available following infusion of 18–48 GBq in 15 patients. Quadramet cleared rapidly from the tissue, with a median biological half-life of 1.4 h. Activity taken up by the skeleton was firmly bound, with activity decreasing according to physical half-life at 24 h in 29 of the 43 cases. The percentage activity retained in the skeleton at 24 h with tracer doses was high (62%±13%), although this decreased to approximately 30% with therapy infusions. Because of this decrease in retention, the maximum feasible therapy activity for this formulation of Quadramet is 35 GBq. Median absorbed marrow radiation dose was 0.78 Gy/GBq in tracer studies: the decreased retention at high activities means that this corresponds to a median dose of 12 Gy for 35 GBq administered activity. It is possible to use 24-h retention as a rough guide to marrow dose in individual patients. In tracer studies, median bladder radiation dose was 0.22 Gy/GBq and radiation dose to the liver was very conservatively estimated at 0.2 Gy/GBq. After therapy infusions of up to 50 GBq in 37 patients, non-haematopoietic toxicity was not seen in any patient. In...


Related Articles

  • Breakthrough in Stem Cell Therapy.  // India -- West;7/16/2010, Vol. 25 Issue 34, pA41 

    The article reports on the success of an autologous stem cell-based therapy procedure in a nine-month-old dog conducted by researchers at Tamil Nadu Veterinary and Animal Sciences in India.

  • Carboplatin/etoposide: Intrapulmonary haemorrhage: case report.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p96 

    A 71-year-old woman developed pruritus and acneiform skin rash during treatment with erlotinib for lung adenocarcinoma. Additionally, the acneiform skin rash and pruritus worsened following concomitant administration of erlotinib and aprepitant for lung adenocarcinoma.

  • Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. Tauro, S; Shankaranarayana, P; Nitu-Whalley, I C; Duncan, N; Begum, G; Craig, J I O; Marcus, R E; Craddock, C F; Mahendra, P // Bone Marrow Transplantation;Aug2003, Vol. 32 Issue 3, p273 

    Summary:Stem cell transplantation (SCT) may be the only curative option for patients with relapsed or refractory leukaemia, that is, high-risk (HR) leukaemia. Several salvage regimens have been used to cytoreduce disease before SCT, but disease progression or treatment toxicity limits numbers of...

  • Impact of new Therapies on Nursing Care.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS255 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S255–S256. DOI: 10.1038/sj/bmt/1703498

  • RESEARCH HIGHLIGHTS. Carroll, Suzanne; Hodges, Lisa; King, Cynthia R. // Oncology Nursing Forum;Jul2006, Vol. 33 Issue 4, p693 

    Summarizes research related to oncology. "Once Weekly Oral Alendronate Prevents Bone Loss in Men in Androgen Deprivation Therapy," by J. B. Nelson, S. L. Greenspan et al.; "Thalidomide and Hematopoietic Stem-cell Transplantation for Multiple Myeloma," by B. Barlogie, G. Tricot et al.; "The...

  • Antithymocyte globulin/cyclophosphamide/etoposide.  // Reactions Weekly;12/18/2010, Issue 1332, p11 

    The article describes the case of a 19-year-old man who presented with acute disseminated fatal toxoplasmosis following stem cell transplantation (SCT) with cyclophosphamide, antithymocyte globulin and etoposide for preconditioning, referencing a study published in the November 2010 issue of the...

  • Azacitidine.  // Reactions Weekly;1/21/2017, Vol. 1635 Issue 1, p52 

    An abstract of the article "Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation" by N. Waespe and others is presented.

  • Antithymocyte-globulin/busulfan/fludarabine/melphalan.  // Reactions Weekly;1/21/2017, Vol. 1635 Issue 1, p41 

    An abstract of the article "T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia" by S. Kobayashi and others is presented.

  • Antineoplastics.  // Reactions Weekly;12/2/2016, Vol. 1630 Issue 1, p20 

    An abstract of the article "Conditioning with thiotepa, treosulfan, fludarabin and rituximab prior allogeneic stem cell transplantation in a patient with relapsed CD20+ oligosecretory multiple myeloma" by A. Nogai and others is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics